$41.37
Value $4.4B
EWTX and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$41.37
Value $4.4B
$349.91
Value $318B
Edgewise Therapeutics (EWTX) has a market value of $4.4B and UnitedHealth (UNH) $318B. Over the last year, with dividends, EWTX moved +85.8% and UNH +12.1%. The P/E is 4.4 for EWTX and 20.0 for UNH. Dividend yield: EWTX none, UNH 2.59%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
EWTX$4.4B
UNH$318B
UNH is 72 times EWTX
Revenue, 12 months
EWTX–
UNH$450B
Net income, 12 months
EWTX$1.0B
UNH$15.9B
UNH is 16 times EWTX
Operating margin
EWTX–
UNH5.3%
ROIC
EWTX-29.0%
UNH11.3%
40.2 points apart
P/E
EWTX4.4
UNH20.0
UNH is 4.5 times EWTX
Dividend yield
EWTX0.0%
UNH2.6%
2.6 points apart
5-year return
EWTX+98.3%
UNH-14.7%
113.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
EWTX+98.3%
UNH-14.7%
| Period | EWTXWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +85.8%Price +85.8% | +12.1%Price +9.2% |
| 3 years since November 17, 2023 | +547.4%+86.4% a yearPrice +547.4% | -30.5%-11.4% a yearPrice -34.8% |
| 5 years since November 17, 2021 | +98.3%+14.7% a yearPrice +98.3% | -14.7%-3.1% a yearPrice -22.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
EWTXEdgewise TherapeuticsUNHUnitedHealth
| Price | $41.37 | $349.91 |
|---|---|---|
| Market value | $4.4B | $318B |
| Enterprise value (EV) | $3.2B | $363B |
| P/E | 4.4 | 20.0 |
| P/E, 5-year median | – | 25.0 |
| P/B | 2.7 | 3.1 |
| EV/EBIT | – | 15.2 |
| Free cash flow yield | – | 7.2% |
| Revenue, 12 months | – | $450B |
|---|---|---|
| Net income, 12 months | $1.0B | $15.9B |
| Free cash flow, 12 months | -$202M | $22.8B |
| Earnings per share, 12 months | $9.41 | $17.52 |
| Revenue growth, year on year | – | 11.8% |
| Revenue growth a year, past | – | +11.7%over 5 years |
| EPS growth a year, past | – | -3.8%over 5 years |
| Gross margin | – | 88.3% |
|---|---|---|
| Operating margin | – | 5.3% |
| Net margin | – | 3.5% |
| ROIC | -29.0% | 11.3% |
| ROE | 138.1% | 15.5% |
| Cash | $1.2B | $28.5B |
|---|---|---|
| Total debt | $3.4M | $74.3B |
| Net debt / EBITDA | – | 1.6 |
| Interest cover | – | 6.2× |
| Dividend yield | – | 2.6% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | – | 1.8% |
| Shareholder yield | – | 4.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($318B) is about 71.6 times Edgewise Therapeutics ($4.4B), at today's prices.
Since November 17, 2021, EWTX's price moved +98.3% and UNH's -22.1%. With dividends: EWTX +98.3% (+14.7% a year), UNH -14.7% (-3.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Edgewise Therapeutics and 2.59% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
At today's price, the P/E is 4.4 for EWTX and 20.0 for UNH. It is the share price over the last twelve months' earnings per share.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.